Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 20;129(8):929-35.
doi: 10.4103/0366-6999.179802.

Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy

Xia-Xia Zhang, Min-Ran Li, Hong-Li Xi, Ying Cao, Ren-Wen Zhang, Yu Zhang, Xiao-Yuan Xu  1
Affiliations

Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy

Xia-Xia Zhang et al. Chin Med J (Engl). .

Abstract

Background: The ultimate goal of hepatitis B treatment is hepatitis B surface antigen (HBsAg) seroclearance. Several factors have been suggested to be associated with the rate of HBsAg reduction in antiviral-naive or lamivudine therapy cohorts. However, there are few studies evaluating the factors during long-term entecavir (ETV) therapy. In the present study, we aimed to evaluate the factors to predict the outcome of ETV therapy for 7 years.

Methods: A total of 47 chronic hepatitis B (CHB) patients treated with ETV monotherapy were included in this study. Liver biochemistry, hepatitis B virus (HBV) serological markers, serum HBV DNA, and HBsAg titers were tested at baseline, 3 months, 6 months, and yearly from 1 to 7. The associations between factors and HBsAg reduction were assessed using multivariate tests with repeated measure analysis of variance.

Results: At baseline, serum HBsAg levels showed a positive correlation with baseline HBV DNA levels (r = 0.625, P < 0.001). The mean HBsAg titers after ETV treatment were significantly lower than the baseline titers (P ranges from 0.025 to 0.000,000,6). The HBsAg reduction rate during the 1st year was greater compared to after 1 year of treatment (P < 0.05). Multivariate test showed that hepatitis B e antigen (HBeAg) seroclearance and/or HBsAg reduction ≥0.5 log10 IU/ml at 6 months had a high negative predictive value (96.77%) for HBsAg seroclearance (P = 0.002, P = 0.012, respectively).

Conclusions: The HBsAg reduction rate during the 1st year was greater than that after 1 year of treatment. Further, HBeAg status and HBsAg levels at month 6 are the optimal factors for the early prediction of HBsAg seroclearance after long-term ETV therapy in CHB patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) The detectable rates of HBV DNA and (b) mean HBsAg throughout 7-year treatment period. HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen.
Figure 2
Figure 2
Mean serum HBsAg reduction in different patients groups stratified by (A) age and (B) HBeAg seroclearance at 6 months (C) HBsAg reduction≥0.5log10 IU/ml at 6 months. HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen.
Figure 3
Figure 3
Predictive values of HBeAg seroclearance at month 6 (a) and HBsAg reduction ≥0.5 log10 IU/ml within 6 months (b) of entecavir treatment on HBsAg seroclearance. HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen.
Figure 4
Figure 4
Kinetics of serum HBsAg titers and HBV DNA in the four patients who achieved HBsAg seroclearance. HBV: hepatitis B virus; HBsAg: Hepatitis B surface antigen.
See this image and copyright information in PMC

References

    1. Ganem D, Prince AM. Hepatitis B virus infection –Natural history and clinical consequences. N Engl J Med. 2004;350:1118–29. doi:10.1056/NEJMra031087. - PubMed
    1. Jiang DK, Wu X, Qian J, Ma XP, Yang J, Li Z, et al. Genetic variation in STAT4 predicts response to interferon-alpha therapy for hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2015 [Epub ahead of print]. doi:10.1002/hep.28423. - PubMed
    1. Wang YJ, Yang L, Zuo JP. Recent developments in antivirals against hepatitis B virus. Virus Res. 2015;213:205–13. doi:10.1016/j.virusres.2015.12.014. - PubMed
    1. Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol. 2013;11:1004–10.e1. doi:10.1016/j.cgh.2013.01.026. - PubMed
    1. Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents chemother. 2015;59:4121–8. doi:10.1128/AAC.00249-15. - PMC - PubMed

Publication types